Arterial Hypotension in Critically Ill Neonatal and Pediatric Patients
Conditions
Brief summary
Blood copeptin will be measured during the routine treatment of neonates, children and adolescents on the Intensive Care Unit of the University Children's Hospital Zurich at different time points (admission, 12, 24, 48, 96, 168 hours after admission). These values will be primarily analysed for their variability and their association with arterial hypotension. Blood samples will be drawn together with otherwise medically indicated blood withdrawals to avoid extra harm. Further, copeptin values will be compared to clinical and vital parameters, all of them open-label available during clinical routine. Copeptin's predictive value for patients' outcome will be analysed as secondary outcome.
Interventions
DIAGNOSTIC_TESTCopeptin in plasma
Copeptin will be measured in EDTA-Plasma. Samples will be stored for batch analyses later.
Sponsors
Vincenzo Cannizzaro
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No
Inclusion criteria
* Age: first day of life until 18th birthday. * Ability of the care taker or the adolescent (if≥14 years of age) to understand verbal and written instructions and informed consent in German.
Exclusion criteria
* Care taker or adolescent (if ≥14 years of age) unwilling to give written informed consent. * Care taker or adolescent (if ≥14 years of age) not understanding German and without a family member able to translate. * Adolescent (if ≥14 years of age) unwilling to give written informed consent following sedation \< 24 hours. * Care takers of long-term sedated (\>24 hours) adolescents (if ≥14 years of age) unwilling to give written informed consent or not present within 24 hours.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood copeptin in arterial normo- and hypotension | Up to 168 hours. | Average change of blood copeptin in patients with both arterial normo- and hypotension and different pathologies. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Length of stay on the intensive care unit | Up to 168 hours. | Association of copeptin values with length of stay on the intensive care unit. |
| Length of respiratory support | Up to 168 hours. | Association of copeptin values with length of respiratory Support. |
| Length and dose of catecholamine therapy | Up to 168 hours. | Association of copeptin values with length and dose of catecholamine therapy. |
| Rate of death | Up to 168 hours. | Rate of death at 28 days. |
Countries
Switzerland
Outcome results
None listed